BioSpace News Archive

Teva Pharmaceutical Industries Ltd. published its 2022 Environmental, Social and Governance Progress Report, which highlights the Company’s achievements, such as completing more than 40% of its 23 long-term targets, including six ahead of schedule.

Novanta Inc., a trusted technology partner to medical and advanced technology equipment manufacturers, reported financial results for the first quarter 2023.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced that it will initiate an open-label Phase 2 exploratory trial to assess the efficacy and safety of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, reported initial clinical data about SER-155.

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the first quarter ended March 31, 2023.

Imalogix, an industry leader in deep learning AI for imaging, announced that world renowned radiology leader and clinical researcher Dr. Ehsan Samei has joined the Imalogix team as its Chief Scientific Advisor.

Lucence unveiled LucenceINSIGHT™, its pioneering multi-cancer early detection blood test, at their US headquarters.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801)and Eli Lilly and Company (“Lilly”, NYSE: LLY), jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection).

Allakos Inc., a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, provided a business update and reported financial results for the first quarter ended March 31, 2023.

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, reported financial results for its first quarter ended March 31, 2023.